Patent focus on cancer chemotherapeutics. II Angiogenesis agents: April 2000 - September 2000

Bibliography

• BECK L, D'AMORE PA: Vascular development: cellular and molecular regulation. FASEB J. (1997) 11:365–373.
   PubMedGoogle Scholar
• AHMAD SA, SHAHEEN RM, LIU W et al: Regulators of colon cancer angiogenesis. Emerging Therapeutic Targets (2000) 4(3):347–359.
   Google Scholar
• TAKEI H, IINO Y, HORIGUCHI J, MAEMURA M et al.: Highest microvessel count as a long-term prognostic factor in Japanese breast cancer patients. Cancer Lett. (2000) 156:109–116.
   PubMedGoogle Scholar
• FONTANINI G, VIGNATI S, BOLDRINI L et al.: Vascular endothelial growth factor is associated with neovascu-larization and influences progression of non-small cell lung carcinoma. Gin. Cancer Res. (1997) 3:861–865.
   Google Scholar
• BIRCH S: Angiogenesis inhibitors: recent disappoint-ments and long term prospects: Datamonitor Market Brief (August 2000). Reference code BFHCO269.
   Google Scholar
• SIAFACA K: Over 1,500 anticancer agents are in active development, with 522 in clinical trials, according to web-based new medicine's oncology knowledgeBASE. PRNewswire via NewsEdge Corporation (8 November 2000).
   Google Scholar
• CLARK AF, BINGAMAN DP, KAPIN MA: Ocular angiostatic agents. Exp. Opin. Ther. Patents (2000) 10 (4):427–448.
   Web of Science ®Google Scholar
• Connell R: Cancer chemotherapeutics - angiogenesis agents: October 1999-march 2000. Exp. Opin. Ther. Patents (2000) 10(6):767–786
   Web of Science ®Google Scholar
• KERBEL RS, VILORIA-PETIT A, KLEMENT G, RAK J: 'Accidental' an ti-angiogenic agents: an ti-on cogene directed signal transduction inhibitors and conven-tional chemotherapeutic agents as examples. Eur. Cancer (2000) 36:1248–1257.
   PubMed Web of Science ®Google Scholar
• SCATENA R: Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodelling-related diseases. Exp. Opin. Invest. Drugs (2000) 9(9):2159–2165.
   PubMedGoogle Scholar
• STERNLICHT MD, BERGERS G: Matrix metalloprote-inases as emerging targets in anticancer therapy: status and prospects. Emerging Therapeutic Targets (2000) 4(5)609–633
   Google Scholar
• SKILES JW, MONOVICH LG, JENG AY: Matrix Metallopro-teinases for treatment of cancer. Annual Reports in Medicinal Chemistry, Chapter 15. (2000) 35:167–176.
   Google Scholar
• BROWN PD: Ongoing Trials with matrix metalloprote-inase inhibitors. Exp. Opin. Invest. Drugs (2000) 9 (9):2167–2177.
   PubMedGoogle Scholar
• SHAW T, NIXON JS, BOTTOMLEY KM: Metalloproteinaseinhibitors: new opportunities for the treatment of rheumatoid arthritis and osteoarthritis. Exp. Opin. Invest. Drugs (2000) 9(7):1469–1478.
   PubMed Web of Science ®Google Scholar
• LINDSEY M, LEE R T: MMP inhibition as a potentialtherapeutic strategy for CHF. Drug News & Perspectives (2000) 13 (6):350–354
   PubMedGoogle Scholar
• CHENG M, DE B, PIKUL S et al.: Design & synthesis ofpip erazin e-based matrix metalloproteinase J. Med. Chem. (2000) 43:369–380.
   Google Scholar
• HAJDUK PJ, BURES M, PRAESTGAARD J, FESIK SW:Privileged molecules for protein binding identified from NMR-based screening. J. Med. Chem. (2000) 43:3443–3447.
   PubMed Web of Science ®Google Scholar
• ALBERT D H, MORGAN D W, MAGOC T et al.: Pr eclinicalpharmacology of ABT-51 8, a novel and potent inhibitor of gelatinase A and B with anti-tumor activity. Clinical Cancer Research (2000) 6:Poster 301 from the 11th NUEORTC•AACR Symposium on New Drugs in Cancer Therapy.
   Google Scholar
• Novel N-hydroxamic acid hydrazide inhibitors ofINF-a synthesis. Exp. Opin. Ther. Patents (2000) 10(101617–1621.
   Google Scholar
• SIEMEISTER G: Angiopoietin/Tie receptor system:emerging targets for therapeutic angiogenesis and anti-angiogenic therapy. Emerging Therapeutic Targets (2000) 4 (3):323–332.
   Google Scholar
• ADAMS SA, SUBRAMANIAN V: The angiogenins: an emerging family of ribonuclease related proteins with diverse cellular functions. Angiogenesis (1999) 3:189–199.
   PubMedGoogle Scholar
• AVIEZER D, COTTON S, DAVID M et al.: Porphyrinanalogues as novel antagonists of fibroblast growth factor and vascular endothelial growth factor receptor binding that inhibit endothelial cell proliferation, tumor progression and metastasis. Cancer Res. (2000) 60(10:2973–2980
   PubMedGoogle Scholar
• MENDEL DB, LAIRD AD, SMOLICH BD et al: Develop-ment of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an. AntiCancer Drug Design (2000)15:29–41.
   PubMedGoogle Scholar
• SUN L, MCMAHON G.: Inhibition of tumor angiogenesisby synthetic receptor tyrosine kinase inhibitors. Drug Disc. Today (2000) 5(8)344–353.
   Google Scholar
• VEIKKOLA T, KARKKAINEN M, CLAESSON-WELSH L, ALITALO K: Regulation of angiogenesis viavascular endothelial growth factor receptors. Cancer Res. (2000) 60:203–212.
   PubMed Web of Science ®Google Scholar
• NEUFELD G, COHEN T, GENGRINOVITCH S, POLTORAK Z: Vascular endothelial growth factor (VEGF) and its receptors. FASAB J. (1999) 13:9–22.
   PubMed Web of Science ®Google Scholar
• GORDON MS: Vascular endothelial growth factor as a target for antiangiogenic therapy. j Clin. Onco/. (2000) 18 (90001):45s-46s.
   Google Scholar
• ARNOLD LD, CALDERWOOD DJ, DIXON RW et al.: Pyrrolo [2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I. Bioorg. Med. Chem. Lett. (2000) 1 0 (19):2167–2170
   Google Scholar
• BURCHAT AF, CALDERWOOD DJ, HIRST GC et al.: Pyrrolo [2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck II. Bioorg. Med. Chem. Lett. (2000) 1 0 (19):2171–2174.
   Google Scholar
• MOUSA SA: Integrins as novel drug discovery targets: potential therapeutic and diagnostic implications. Emerging Therapeutic Targets (2000) 4 (2):143–153.
   Google Scholar
• KERR JS, SLEE AM, MOUSA SA: Small molecule avintegrin antagonists: novel anticancer agents. Exp. Opin. Invest. Drugs (2000) 9(6):1271–1279.
   PubMed Web of Science ®Google Scholar
• Several Angiogenesis inhibitors show potential in the lab. J. Natl. Can. Inst. (2000) 92(7):522.
   Google Scholar
• SORBERA LA, GRAUL A, CASTANER J: Cilengitide. Drugs of the Future (2000) 25(7):674–678.
   Google Scholar
• DUGGAN ME, HUTCHINSON JH: Iigands to the integrin receptor avb3. Exp. Opin. Ther. Patents (2 0 0 0) 10 (9) :1367-1383.
   Google Scholar
• ROSE DM, POZZI A, ZENT R: Integrins as therapeutic targets. Emerging Therapeutic Targets (2000) 4 (3):397–411.
   Google Scholar
• MILLER WH, KEENAN RM, WILLETTE RN, LARK MW: Identification and in vivo efficacy of small molecule antagonists of integrin avb3 (the vitronectin receptor). Drug Discovery Today (2000) 5(9):397–408.
   PubMedGoogle Scholar
• MILLER WH, ALBERTS DP, BHATNAGAR PK et al. Discovery of orally active non-peptide vitronectin receptor antagonists based on 2-benzazepine Gly-Asp-mimetic. J. Med. Chem. (2000) 43:22–25.
   PubMed Web of Science ®Google Scholar
• PITTS WJ, WITYAK J, SMALLHEER JM et al.: Isoxazolines as potent antagonists of the integrin avb3. j Med. Chem. (2000) 43:27–40.
   PubMed Web of Science ®Google Scholar
• HEERDING D, MILLER WH, WILLETTE R et al.: Discovery of orally active vitronectin receptor (av133) receptor antagonists. ACS National Meeting. (2000) MEDI No. 175.
   Google Scholar
• DUGGEN M, DUONG LT, FERNANDEZ-METZLER C et al.: Design & synthesis of potent av133 antagonists: discovery of 5,6,7,8-tetrahydro[1,8]naphthyridine as a lipophilic, moderately basic guanidine replacement. ACS National Meeting (2000) MEDI No. 166.
   Google Scholar
• DUGGAN ME, DUONG LT, FISHER JE et al.: Nonpeptide avb3 antagonists. 1. Transformation of a potent, integrin-selective allbb3 antagonist into a potent avb3 antagonist. J. Med. Chem. (2000) 43 (20):3736–3745
   Google Scholar
• KUMAR CC, NIE H, ROGERS CP et al.: Biochemicalcharacterization of the binding of echistatin to alphavbeta3 receptor. Pharmacol. Exp. Ther. (1997) 283 (2):843–53
   PubMedGoogle Scholar
• NIIYA K, HODSO E, BADER R et al.: Increased surfaceexpression of the membrane glycoprotein complex induced by platelet activation. Relationship to the binding of fibrinogen and platelet aggregation. Blood (1987) 70(2):475–83.
   Google Scholar
• LUNA J, TOBE T, MOUSA SA, REILLY TM, CAMPOCHIAROPA: Antagonists of integrin alpha v beta 3 inhibit retinal neovascularization in a murine model. Lab. Invest. (1996) 75(4):563–573.
   PubMed Web of Science ®Google Scholar
• ZHOA Q, NAKADA MT, ARNOLD C, SHIEH KY, MARKLAND JR FS: Contortrostatin, a dimeric disintegrin from agkistrodon contortrix contortrix, inhibits angiogenesis. Angiogenesis (2000) 3:259–269.
   Google Scholar
• BATT DG, PETRAITIS JJ, HOUGHTON GC et al: Disubsti-tuted indazoles as potent antagonists of the integrin avb3. J. Med. Chem. (2000) 43:41–58.
   PubMed Web of Science ®Google Scholar
• ANDERSON CJ, LEWIS JS: Radiopharmaceuticals for targeted radiotherapy in cancer. Exp. Opin. Ther. Patents (2000) 10 (7) :1057–1069.
   Web of Science ®Google Scholar
• KENNETT RH: Antibodies to target integrins expressed on tumor vasculature. Current Opin. Oncol. Endocr. Metab. Invest. Drugs (2000) 2(4)376–380.
   Google Scholar
• NELSON NJ: Plasminogen activator proteins tested as prognostic markers. J. Natl. Can. Inst. (2000) 92:866–868
   PubMedGoogle Scholar
• DUNBAR SD, ORNSTEIN DL, ZACHARSKI LR: Cancer treatment with inhibitors of urokinase-type plasmi-nogen activator and plasmin. Exp. Opin. Invest. Drugs (2000) 9 (9) 2085–2092.
   PubMed Web of Science ®Google Scholar
• ROCKWAY TW, MCCLELLAN WJ, DELLARIA JF et al: Structure based design of novel urokinase inhibitors derived from 2-Naphthamidine. ACS National Meeting. (2000) MEDI–30.
   Google Scholar
• TAMURE SY, WEINHOUSE MI, ROBERTS CA, GOLDMAN EA et al.: Synthesis and biological activity of peptidyl aldehyde urokinase inhibitors. Biorg. Med. Chem. Lett. (2000) 10:983–987.
   PubMedGoogle Scholar
• NOVAK K: Angiogenesis team sued by pharmaceutical company. Nat. Med. (2000) 6(7):723
   PubMedGoogle Scholar
• NOVAK K: Folkman countersuit attacks 'fraudulent' Abbott. Nat. Med. (2000) 6(9):948
   PubMedGoogle Scholar
• O'REILLY MS, PIRIE-SHEPHERD S, LANE WS, FOLKMAN J Antiangiogneic activity of the cleaved conformation of the serpin antithrombin. Science (1999) 285:1926–1928.
   PubMed Web of Science ®Google Scholar
• VANCHIERI C: Cutting copper curbs angiogenesis, studies show. J. Natl. Cancer Inst. (2000) 92 (15) :1202–1203
   PubMedGoogle Scholar
• DAVIS PD, HILLS A, CHAPLIN D J AND DOUGHERTY G J:Anti-tumour activity of vascular targeting agent ZD6126 is enhanced by split dosing. Clin. Cancer Res. (2000) The I I th NCIEORMAACR Symposium on New Drugs in Cancer Therapy. 6:Poster 282.
   Google Scholar
• TAKEI H, LEE ES, CISNEROS A, JORDAN VC: Effects ofangiogenesis inhibitor TNP-470 on tamoxifen- MCF-7 breast tumors in nude mice. Cancer Lett. (2000) 129–135.
   PubMedGoogle Scholar
• KRUGER EA, FIGG WD: TNP-470: an angiogenesis inhibitor in clinical development for cancer. Exp. Opin. Invest. Drugs (2000) 9(6):1383–1396.
   PubMed Web of Science ®Google Scholar
• MOORE JD, DEZUBE BJ, GILL P, ZHOU X-J, ACOSTA EP: Phase I dose escalation pharmacokinetics of 0-(chloroacetylcarbonyl) fumagillol (TNP-470) and its metabolites in AIDS patients with karposi's sarcoma. Cancer Chemother. Pharmacol. (2000) 46:173–179.
   PubMed Web of Science ®Google Scholar
• SEDLACEK HH: Kinase inhibitors in cancer therapy. Drugs (2000) 59(3):435–476.
   PubMedGoogle Scholar
• WILKINSON S E, HARRIS W: Selective tyrosine kinaseinhibitors. Emerging Drugs (2000) 5 (3):287–297.
   Google Scholar